Looking to gene therapy for ocular diseases, with Lance Baldo

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Lance Baldo, CEO of Beacon Therapeutics, a clinical-stage biotechnology company harnessing the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.

Baldo discusses the ocular disease landscape, as well as Beacon’s work targeting X-linked retinitis pigmentosa (XLRP) and geographic atrophy (GA), and what the future could look like in terms of innovation in this field.

You can listen to episode 253 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.